Abstract: A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R1 and R2 independently represents —H or —OH; R3 represents —OH; R4 represents —OH or —H; R5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.

Abstract: An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression. A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.

Abstract: The present invention relates to a method for reducing the HTO concentration in a tritium-containing aqueous solution. The present invention includes bringing water vapor or the like of a tritium-containing aqueous solution into contact with a porous material having pores in a pore diameter range of 500 ? or less, selectively occluding the HTO in the tritium-containing aqueous solution in the porous material, and obtaining a tritium-containing aqueous solution in which the HTO concentration thereof is reduced. The present invention relates to a device used for reducing the HTO concentration in a tritium-containing aqueous solution.

Abstract: To improve the fact that the main components of conventional deodorizing and antimicrobial agents are existing components, the effect and efficacy of which are known to some extent, and do not generate an effect better than predicted. The deodorizing and antimicrobial agent of the present invention has a loquat seed extract including non-volatile fatty acids and at least benzaldehyde and benzoic acid as a main raw material.

Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a 5-membered heteroaryl group or a fused ring of a 5-membered or 6-membered heterocyclic ring with a benzene ring or a pyridine ring, each of which may have a substituent; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent, or the like; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2.

Abstract: An object is to provide a cell culture scaffold which makes it possible to recover a cell culture product without being destroyed after cell culturing and a method for producing a cell culture product. The cell culture scaffold according to the present invention includes a substrate having a water-repellent surface and a cell adhesion molecule formed on the water-repellent surface of the substrate. Further, the method for producing a cell culture product according to the present invention includes a step of culturing, using the cell culture scaffold, cells on the surface of the cell adhesion molecule. The cell culture scaffold according to the present invention makes it possible to recover the cells in a spheroid state without causing a damage.

Abstract: A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compound, a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an active ingredient.

Abstract: A compound represented by General Formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, or a solvate thereof is used as a voltage-dependent T-type calcium channel inhibitor, in the formula, A represents a benzene ring which may have a substituent or the like; B represents a hetero-fused ring consisting of a 5- or 6-membered heteroaryl ring having one to three same or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom, and a carbon atom, as a ring-constituting atom, and a benzene ring, or the like, and the hetero-fused ring may have a substituent, and is bonded to a cyclopropyl group via a carbon atom constituting these rings; R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like; R2 and R3 may be the same as or different from each other, and each represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, or the like, or R2 and R3 together form CH2CH2 or the like; R4 represents a hydr

Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.

Abstract: Phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. However, there is a problem that an amount of phytol to be taken for exhibiting cancer cell growth inhabition is large. A cancer cell growth inhibiting composition comprising at least one of compounds having a structure represented by Formula (1), Formula (2), Formula (6), Formula (7) or Formula (8), or a pharmaceutically acceptable salt thereof as main components has a higher cancer cell growth inhibiting effect than phytol.

Abstract: No drug has been available for treating a peripheral sensory neuropathy caused as a side effect by a drug, in particular, by an anticancer drug such as oxaliplatin. A composition for ameliorating peripheral sensory neuropathy, which is characterized by including a Lentinus edodes mycelium extract, ameliorates symptoms induced by the drug such as the anticancer drug, including numbness of extremities, a pain in extremities, a reduction in deep tendon reflection, a reduction in muscle force, allodynia, hyperalgesia, impaired finger fine movement, impaired walking, stumbling, falling, impaired flexion (being difficult or impossible to sit on one's heels, sit cross-legged, sit with one's legs out to one side, sit on a chair, or the like), or paralysis of extremities.

Abstract: A nerve cell culture material including LASCol has the effect of successfully maintaining survival of the nerve cell. Furthermore, a therapeutic agent for nerve damage including LASCol can allow an endogenous nerve cell to infiltrate or proliferate actively in vivo, thereby enabling neurites to extend early and bind to each other, and has an effect on nerve damage, the effect being sufficient to improve a BBB score.

Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.

Abstract: Disclosed is a method for assisting a determination of an efficacy of an immune checkpoint inhibitor, the method comprising: measuring a free protein marker in a liquid sample collected from a subject; and determining the efficacy of the immune checkpoint inhibitor in the subject based on a result of the measurement, wherein the free protein marker is at least one selected from free Cytotoxic T lymphocyte antigen-4 (CTLA-4), free Programmed cell death-1 (PD-1) and free Programmed cell death-ligand 1 (PD-L1).

Abstract: A so-called molecular-targeted drug acting on a signal transduction pathway in a cell has been developed. However, a side effect of the molecular-targeted drug is not negligible for a patient. Thus, there has been a demand for a substance that exhibits a significant growth inhibitory effect on a cancer cell with fewer side effects as a health food and a pharmaceutical composition. It has been found that a hexane extract fraction of a watermelon sprout has an effect of specifically inhibiting the cell growth of the cancer cell and such an effect is primarily caused by phytol and lutein. A processed food and pharmaceutical composition having these substances as main components can exert an anticancer action without causing side effects.

Abstract: A treatment method is capable of degrading or sterilizing harmful substances or microorganisms of which the degradation, detoxification, or the like is not easy for ozone gas alone. A harmful substance treatment method is one that makes ozone gas act on harmful substances, microorganisms, or the like in an environment humidified using a surfactant solution. The harmful substances include anticancer drugs. As a surfactant to be used, a non-ionic surfactant, an anionic surfactant, a cationic surfactant, or an amphoteric surfactant can be used.

Abstract: A medicament effective for prophylactic and/or therapeutic treatment of a peripheral neuropathic pain such as allodynia caused by a treatment with an anticancer agent, which comprises thrombomodulin as an active ingredient.

Abstract: A fluorene derivative represented by General Formula (1) below. X1—Y—X2??General Formula (1) In the General Formula (1), X1 represents a cyclic carbonate group including a carbonate bond [—O—C(?O)—O—], X2 represents a cyclic carbonate group including a carbonate bond [—O—C(?O)—O—], and Y represents a bivalent group including a 9,9-bisaryl fluorene skeleton.

Abstract: A CT value controller includes a storage means, an input means, and a computing means. The storage means stores a function expressing a relative humidity and a CT value regarding a degradation degree of an anticancer agent, an assumed relative humidity, and a CT setting. The input means inputs a measured relative humidity and a measured ozone concentration at a time of degradation treatment of the anticancer agent. The computing means calculates a corrected CT value increment based on a difference between the measured relative humidity and the assumed relative humidity at every input of the relative humidity and the ozone concentration by using the function. The computing means determines a termination of the degradation treatment of the anticancer agent when an integrated CT value of the corrected CT value increments reaches the CT setting.

Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.